Concomitant use of H1 antihistamines improves survival outcomes in cancer patients on immune checkpoint inhibitor therapy: a systematic review and meta-analysis [0.03%]
H1抗组胺药联合免疫检查点抑制剂治疗改善癌症患者的生存结局：系统评价和Meta分析
Francisco Cezar Aquino de Moraes,Pedro Henrique de Souza Wagner,Rosario Dominguez Crespo Hirata et al.
Francisco Cezar Aquino de Moraes et al.
Introduction: The rapid progress of immuno-oncology has transformed cancer pharmacotherapy through immune checkpoint inhibitors (ICIs); however, only a minority of patients experience durable benefits. Recent evidence sug...
Authors' response to the comment on "upper and lower limb cryotherapy as a preventive strategy for taxane-induced peripheral neuropathy in breast cancer patients: a systematic review and meta-analysis" [0.03%]
-taxane诱导的周围神经病变系统评价和meta分析-作者回信
Anderson Matheus Pereira da Silva,Patrick F Meldola,Wilson C N de Castro et al.
Anderson Matheus Pereira da Silva et al.
Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18.2-positive gastroesophageal adenocarcinoma [0.03%]
针对胃谱系的免疫疗法zolbetuximab：Claudin18.2阳性胃食管腺癌中的作用原理和转化证据
Kristian Egebjerg,Florian Lordick,Lisa L Liu et al.
Kristian Egebjerg et al.
Introduction: Zolbetuximab is a first-in-class monoclonal antibody targeting claudin 18.2 (CLDN18.2) demonstrating clinical benefit in gastroesophageal adenocarcinomas. CLDN18.2 is a gastric lineage-restricted tight-junct...
Effectiveness and cost-effectiveness of first-line versus second-line use of repotrectinib in the treatment of ROS1 fusion-positive advanced NSCLC [0.03%]
普纳替尼一线治疗与二线用于ROS1融合阳性晚期非小细胞肺癌的有效性及成本效益分析
Gengwei Huo,Peng Chen
Gengwei Huo
Background: This study evaluated the cost-effectiveness of repotrectinib as first-line versus second-line therapy compared with chemotherapy for advanced ROS1 fusion - positive non-small cell lung cancer (NSCLC) from a U....
Impact of renin-angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non-small cell lung cancer [0.03%]
血管紧张素系统抑制剂对转移性非小细胞肺癌患者nivolumab治疗临床疗效的影响研究
Emel Mutlu Ozkan,Ibrahim Karadağ,Elif Sahın et al.
Emel Mutlu Ozkan et al.
Background: The objective of this study is to evaluate the correlation between survival outcomes and renin angiotensin system inhibitors (RASI) use in patients treated nivolmab with metastatic non-small cell lung cancer (...
New horizons for hope of cure in acute myeloid leukemia through immunotherapy: a narrative review [0.03%]
免疫治疗为急性髓系白血病的治愈带来新的希望：叙事性综述
Pasquale Niscola,Valentina Gianfelici,Gloria Pasqualini et al.
Pasquale Niscola et al.
Introduction: Acute Myeloid Leukemia (AML) is a challenging blood cancer characterized by a high rate of relapse and often unfavorable outcomes. Immunotherapies can pave the way for a changing paradigm in AML treatment an...
Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events [0.03%]
皮质类固醇治疗对发生免疫相关不良事件的转移性实体瘤患者生存率的影响
Caner Acar,Gökhan Şahin,Haydar Çağatay Yüksel et al.
Caner Acar et al.
Background: Immune checkpoint inhibitors (ICIs) improve survival in solid tumors but can cause immune-related adverse events (irAEs) that often require systemic steroids. The impact of steroid dose and timing on ICI effic...
Prognostic factors of undifferentiated embryonal sarcoma of the liver in children: a SEER-based study [0.03%]
儿童肝脏未分化胚胎性肉瘤的预后因素：基于SEER数据库的研究
Qiu Jin,Yehang Zhu,Zhaopeng He
Qiu Jin
Background: This study aimed to evaluate the clinical characteristics and identify prognostic variables affecting overall survival (OS) in children with undifferentiated embryonal sarcoma of the liver (UESL) using data fr...
An evaluation of afamitresgene autoleucel for the treatment of advanced synovial sarcoma and myxoid round cell liposarcoma [0.03%]
afamitresgene autoleucel治疗高级别滑膜肉瘤和黏液样圆形细胞脂肪肉瘤的评估
Margaux Dupont,Armelle Dufresne,Mehdi Brahmi et al.
Margaux Dupont et al.
Introduction: Synovial sarcoma (SyS) and myxoid round-cell liposarcoma (MRCL) are rare, aggressive soft tissue sarcomas with poor outcomes at the advanced and metastatic stage. Novel therapeutic strategies are urgently ne...
Elacestrant in metastatic breast cancer: current advancements and future perspectives [0.03%]
埃尔罗西坦治疗转移性乳腺癌：目前进展与未来展望
Taha Koray Sahin,Binura Makasheva,Deniz Can Guven et al.
Taha Koray Sahin et al.
Introduction: Hormone receptor-positive and HER2-negative advanced breast cancer is the most prevalent subtype and poses therapeutic challenges. While endocrine therapy remains the cornerstone of management, acquired resi...